Oncologist-approved cancer information from the American Society of Clinical Oncology

Prostate Cancer

News and highlights from ASCO Annual Meetings.


Category :
Year :
 
 
Type of Specialist Consulted Affects Prostate Cancer Treatment Decisions
June 3, 2007

The type of treatment men choose for localized prostate cancer is influenced by the type of doctor they see, according to a new study.
Flaxseed May Delay Prostate Cancer Growth
June 2, 2007

Adding flaxseed to the diet of men with prostate cancer may slow the growth of the cancer, but lowering dietary fat has no effect on prostate cancer growth, a new study suggests.
Drug May Lower Risk of Developing Prostate Cancer
May 14, 2005

Results of a large phase II clinical trial show that a hormone drug called toremifene (Acopodene) lowers the risk of prostate cancer by nearly half for men with prostatic intraepithelial neoplasia (PIN).
Chemotherapy Improves Survival and Quality of Life for Patients with Hormone-Refractory Prostate Cancer
June 7, 2004

Two new studies demonstrate that docetaxel (Taxotere) extends survival and relieves pain in men with prostate cancer that does not respond to hormone therapy.
Hormone Therapy For Non-Metastatic Prostate Cancer Increases Risk of Bone Fractures
June 5, 2004

A new study suggests that men taking a specific type of hormone therapy, called gonadotropin-releasing hormone (GnRH) agonists, for prostate cancer are at an increased risk of bone fractures. This risk increases the longer the treatment continues. GnRH agonists work by limiting production of the hormone testosterone. This type of hormone therapy is also called androgen deprivation therapy (androgens are male sex hormones).
<<Previous | Page 1 of 1 | Next>>